生物医药企业Repare Therapeutics Inc.（纳斯达克代码：RPTX）15日宣布与瑞士制药公司Debiopharm达成重大战略合作。根据协议条款，Debiopharm获得抗癌药物Lunresertib的全球独家开发及商业化权利。
Repare公司将立即获得1000万美元首付款，并有资格获取最高达2.57亿美元的里程碑款项。协议规定Debiopharm将主导Lunresertib的MYTHIC临床研究项目，全面负责该候选药物的后续开发工作。
Lunresertib作为新型DNA损伤修复抑制剂，在临床前研究中展现出治疗多种实体瘤的潜力。此次合作将加速该创新疗法的全球开发进程，为Repare带来重要的非稀释性资金支持。交易完成后，Repare保留在美国市场共同推广的选择权，并有权获得大中华区以外的全球销售分成。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.